Medications, Board Hypoxia is a key indicator often associated with severe disease and a poor outcome. Toggle Summary. We cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug … ... Adamis Pharmaceuticals Announces FDA Acceptance for Review for the Supplemental New Drug Application of Its Low Dose Symjepi Product Candidate. There can be no assurances regarding the outcome of our submission of the IND relating to investigational use of, or trials or studies relating to, Tempol, regarding the timing or the outcome of any applications or requests that we may submit for government or other funding for studies or trials relating to Tempol; concerning the timing or outcome of any such studies or trials; or that Tempol will be found to be safe and effective in the treatment of COVID-19 or any other indication. ADMP Adamis Pharmaceuticals Corporation — Stock Price and Discussion | Stocktwits. Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in … With new mutations occurring in the virus, it is apparent there is an ongoing need for new therapies. of Directors, Privacy Directors, Customized ET Adamis Pharmaceuticals has been expecting an approval letter from the FDA regarding its naloxone product candidate, ZIMHI. Directors, Customized SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA… Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in … Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a specialty of Directors, Privacy The company’s SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the … These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis' actual results to be materially different from the results anticipated by such forward-looking statements. Statement. Shares of Adamis Pharmaceuticals Corporation ADMP surged 77.6% after it submitted an investigational new drug (IND) application to the FDA … We believe that Tempol could play a pivotal role not only in the treatment of COVID-19, but actually in preventing hospitalization. Adamis Pharmaceuticals Receives FDA Approval for Its Epinephrine Pre-Filled Syringe. Numerous published articles describing animal models of ARDS show Tempol to cause a decrease in lung inflammation and preserve lung pathology associated with acute and chronic lung injury. As discussed in our filings with the Securities and Exchange Commission, we will require additional funding, and there are no assurances that such funding will be available if required. Board of products in the therapeutic areas of respiratory disease and allergy. The clearance to proceed follows the submission of an IND application to FDA … Symjepi (epinephrine) Injection 0.3mg is an FDA-approved product, for the emergency treatment of allergic reactions (Type I) including anaphylaxis, designed for patients weighing 66 pounds or greater. With its lead pipeline product and specialty pharmaceutical pipeline, ADMP is poised to become a leader in the specialty biopharmaceutical industry. SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi ™ for the emergency treatment of allergic reactions (Type I) including anaphylaxis. To this end, Tempol has been shown to decrease the genes (HIF-la and HIF-2a) associated with hypoxia. Medications, Board Mark Flather Senior Director, Investor Relations& Corporate Communications (858) [email protected], Source: Adamis Pharmaceuticals Corporation, 2021 Copyright Adamis Pharmaceuticals Corporation, Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product. Tempol has demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity. The lower dose version (0.15mg) is intended to potentially treat patients weighing 33-66 pounds.  Both Symjepi products will provide two single-dose injections syringes of epinephrine (adrenaline), which is considered the drug of choice for immediate administration in acute anaphylactic reactions to allergic reaction to foods (such as nuts), insect stings or bites, drugs and other allergens, as well as idiopathic or exercise-induced anaphylaxis. Press Release Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19 Published: Jan. 20, 2021 at 9:00 a.m. DOW 0.48%. Dr. Dennis J. Carlo, President and CEO of Adamis commented: “With over 23 million COVID-19 infections in the US and over 394,000 deaths in the US (according to the CDC), additional treatments are urgently warranted. Both inflammatory cytokines and reactive oxygen species (ROS) from cells of the immune system called macrophages and neutrophils damage the lung in Acute Respiratory Distress Syndrome (ARDS). The company’s Symjepi (epinephrine) Injection products (0.3mg and 0.15mg) have been approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis.  Adamis recently announced a distribution and commercialization agreement with Sandoz, a division of Novartis Group, to market both doses of Symjepi in the U.S. market.  Adamis is developing a sublingual tadalafil product candidate as well as two products for the treatment of asthma and COPD.  The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use, to patients, physician clinics, hospitals, surgery centers and other clients throughout most of the United States. Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19 SAN DIEGO , Jan. 20, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). Board of The Company plans to seek government and/or non-government funding to study the treatment and prevention of COVID-19 with Tempol. January 20, 2021 - 9:00 am. Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Adamis… The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA … These statements relate to future events or future results of operations, including, but not limited to the following statements: the company’s beliefs concerning the safety and effectiveness of Tempol or the company’s other product candidates; the timing of funding for, or commencement or completion of, any studies or trials relating to Tempol; the availability of, and the company’s success in applying for and obtaining, government or other funding for studies or trials relating to Tempol or the timing or amount of any such funding; the results of any future studies or trials that the company may conduct relating to Tempol; the company’s ability to commercialize the product candidates described in this press release, itself or through commercialization partners; and other statements concerning our future operations and activities. biopharmaceutical company focused on developing and commercializing pharmaceutical products in the therapeutic areas of respiratory disease and allergy. The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. Feb 17, 2021. drugs approved by the U.S. Food and Drug Administration, or the FDA. SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company") announced today that the U.S. Food and Drug Administration ("FDA") has completed the safety review of the Company's Investigational New Drug ("IND") application and has concluded that Adamis may proceed with the proposed clinical investigation of Tempol for the treatment of COVID-19.